Ceredex Value Advisors LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Ceredex Value Advisors LLC has acquired a new position in Regeneron Pharmaceuticals, purchasing 31,025 shares valued at approximately $19.7 million in the 1st quarter.
• Institutional investors collectively own 83.31% of Regeneron Pharmaceuticals' stock, with significant increases in holdings from several firms during the same quarter.
• Regeneron Pharmaceuticals reported an earnings per share of $12.89 for the most recent quarter, exceeding analyst estimates and reflecting a 3.6% increase in revenue year-over-year.

Ceredex Value Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 31,025 shares of the biopharmaceutical company's stock, valued at approximately $19,677,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Adirondack Trust Co. grew its position in Regeneron Pharmaceuticals by 4.2% during the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 18 shares during the period. Kingswood Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after purchasing an additional 19 shares during the period. Creative Financial Designs Inc. ADV grew its position in shares of Regeneron Pharmaceuticals by 9.5% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after acquiring an additional 19 shares during the period. Private Trust Co. NA grew its position in shares of Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after acquiring an additional 19 shares during the period. Finally, Proficio Capital Partners LLC grew its position in shares of Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after acquiring an additional 19 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. Jefferies Financial Group raised their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research report on Wednesday. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Canaccord Genuity Group restated a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, The Goldman Sachs Group decreased their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Price Performance

REGN traded down $7.35 during trading on Thursday, reaching $579.61. The company's stock had a trading volume of 616,549 shares, compared to its average volume of 1,082,231. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $555.84 and a two-hundred day simple moving average of $588.67. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,210.97. The company has a market cap of $61.43 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 1.96 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's revenue was up 3.6% on a year-over-year basis. During the same period last year, the company posted $11.56 EPS. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.